ArticleHealth services research2018
Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.
Article in Health services research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review.Journal of managed care & specialty pharmacy · 2023Pooled it
- Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.Exploratory research in clinical and social pharmacy · 2023Article
- Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.BMC neurology · 2022Article
- Inequity and the Interstitium: Pushing Back on Disparities in Fibrosing Lung Disease in the United States and Canada.American journal of respiratory and critical care medicine · 2022Article
- Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program.Neurology. Clinical practice · 2022Article
- Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs.Neurology. Clinical practice · 2021Article
- Medication Costs Harm Patients With Multiple Sclerosis.Neurology. Clinical practice · 2021Article
- Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.Current neurology and neuroscience reports · 2021Review
- Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes.Chest · 2021Article
- Health economics of disease-modifying therapy for multiple sclerosis in the United States.Therapeutic advances in neurological disorders · 2021Review
- Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population.International journal of MS careArticle
- Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the impact of cost-sharing increases on continuity of specialty drug use in Medicare beneficiaries with multiple sclerosis (MS) or rheumatoid arthritis (RA). DATA SOURCES/STUDY
settingFive percent Medicare claims data (2007-2010). STUDY
designQuasi-experimental study examining changes in specialty drug use among a group of Medicare Part D beneficiaries without low-income subsidies (non-LIS) as they transitioned from a 5 percent cost-sharing preperiod to a ≥25 percent cost-sharing postperiod, as compared to changes among a disease-matched contemporaneous control group of patients eligible for full low-income subsidies (LIS), who faced minor cost sharing (≤$6.30 copayment) in both the pre- and postperiods. DATA COLLECTION/EXTRACTION
methodsKey variables were extracted from Medicare data. PRINCIPAL
findingsRelative to the LIS group, the non-LIS group had a greater increase in incidence of 30-day continuous gaps in any Part D treatment from the lower cost-sharing period to the higher cost-sharing period (MS, absolute increase = 10.1 percent, OR = 1.61, 95% CI 1.19-2.17; RA, absolute increase = 21.9 percent, OR = 2.75, 95% CI 2.15-3.51). The increase in Part D treatment gaps was not offset by increased Part B specialty drug use.
conclusionsCost-sharing increases due to specialty tier-level cost sharing were associated with interruptions in MS and RA specialty drug treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.